White House Says WTO Waiver May Not Be Best Way to Spur Vaccines

April 29, 2021, 1:40 PM

The U.S. focus on increasing supply of Covid-19 vaccines for other countries may mean boosting manufacturing at American facilities rather than waiving intellectual-property protections for doses, the White House said.

U.S. Trade Representative Katherine Tai, who has been holding meetings with vaccine producers and groups advocating a temporary suspension of rules at the World Trade Organization, has yet to make a recommendation to the White House on the waiver proposal, White House Press Secretary Jen Psaki said in an interview with CNN Thursday. President Joe Biden and his Covid-19 team will then make the ultimate decision on the U.S....

To read the full article log in.

Learn more about a Bloomberg Law subscription.